Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

@article{Butts2007RandomizedPI,
  title={Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.},
  author={Charles Andrew Butts and David J. Bodkin and Edward L Middleman and Craig W Englund and David Ellison and Yasmin Alam and Harvey Kreisman and Peter R Graze and James Maher and Helen J. Ross and Peter M. Ellis and William E. McNulty and Edward A Kaplan and Virginie Pautret and Martin R Weber and Frances A. Shepherd},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 36},
  pages={5777-84}
}
PURPOSE To evaluate the efficacy of cetuximab added to first-line gemcitabine/platinum in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS In this noncomparative, randomized trial, chemotherapy-naïve patients with recurrent/metastatic NSCLC (stage IV or stage IIIB with malignant pleural effusion) were eligible. Patients received cisplatin (75 mg/m2 i.v., every 3 weeks) or carboplatin (area under the concentration-versus-time curve of 5… CONTINUE READING